DEA Slaps Another Year on Five Frankenstein Benzo Drugs
Published Date: 7/25/2025
Rule
Summary
The DEA is extending the temporary Schedule I status for five designer drugs—clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam—for one more year or until permanent rules are set. This means anyone making, selling, or using these drugs will keep facing strict legal controls and penalties. If you work with these substances, get ready to follow the same tough rules for now!
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
One-Year Extension of Schedule I Controls
The DEA is extending the temporary Schedule I status of clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam for one year or until permanent rules are set. If you make, sell, import, export, research, teach about, chemically test, or possess these drugs, you will continue to be subject to the strict regulatory controls and administrative, civil, and criminal penalties that apply to Schedule I substances.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20226, By Grace Inc. Counseling Services; Decision and Order
By Grace Inc. Counseling Services in Baltimore faced losing its DEA license because it didn’t keep good records and lied about its owner’s past drug conviction. After a hearing, the DEA decided to revoke their registration, meaning they can’t legally handle controlled substances anymore. This affects the clinic’s ability to operate and could impact patients relying on their services.
2026-20227, St. Michael's Pharmacy; Decision and Order
St. Michael's Pharmacy in Texas had its DEA license suspended and is facing revocation because it kept filling risky drug prescriptions without fixing obvious warning signs of abuse. This affects the pharmacy’s ability to legally handle controlled substances and could impact patients relying on it. The pharmacy must now deal with these serious legal actions, which started in late 2025 and could lead to permanent closure or fines.
Previous / Next Documents
Previous: 2025-14013, Program Originating FM Broadcast Booster Stations
The FCC just gave the green light for FM booster stations to create their own content permanently, making it easier for local radio to shine. Broadcasters using these boosters will need to file a new form to keep the FCC in the loop. These changes kick in soon, so stations should get ready to boost their voices without extra costs!
Next: 2025-14040, Amendment of VOR Federal Airways V-38, V-133, and V-144, and Revocation of VOR Federal Airway V-214 in the Vicinity of Zanesville, OH
The FAA is updating some flight paths near Zanesville, Ohio, by changing routes V-38, V-133, and V-144, and removing route V-214. This happens because the Zanesville navigation beacon is being turned off as part of a plan to modernize air travel. Pilots flying in this area will need to follow the new routes starting soon, but there’s no extra cost for travelers.